ClinicalTrials.gg
RecruitingNCT05627713PoxVac22Updated Dec 19, 2023

Clinical and Biological Aspects of the MONKEYPOX Disease

An interventional study of Blood sample collection and urine sample collection in Monkey Pox, sponsored by Institut Pasteur. Recruiting at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-19.

Sponsored by Institut Pasteur · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Started Dec 2022; still recruiting 3 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
330
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Monkey pox virus (MPXV), of the genus Orthopoxvirus, regularly causes epidemics in endemic areas of central and western Africa.

Since January 1, 2022, cases of Monkey pox have been reported to WHO by 96 Member States in the 6 WHO regions. As of 22 August 2022, a total of 41,664 laboratory-confirmed cases and 192 probable cases, including 12 deaths, have been reported to WHO. Since May 13, 2022, a high proportion of these cases have been reported from countries where monkey pox transmission had not previously been documented. For the first time, cases and sustained chains of transmission are being reported in countries without direct or immediate epidemiological links to areas in West or Central Africa (WHO 2022). France is one of the most affected countries with 2889 cases reported as of August 22, 2022.

This situation led the WHO Director General to declare, on July 23, 2022, that the monkeypox epidemic currently affecting several countries constitutes a Public Health Emergency of International Concern.

To address this epidemic, the WHO has recommended Post Exposure Vaccination (PEP) and Pre Exposure Vaccination (PrEP) for at risk groups with 2nd and 3rd generation vaccines. In France, the Haute Autorité de Santé (French National Authority for Health) recommended on May 20, 2022, vaccination for PEP and on July 7, 2022, for PrEP with a 3rd generation MVA-BN vaccine (Imvanex® or Jynneos®). The European Medicines Agency (EMA) has approved the use of Imvanex® on July 22, 2022 for immunization against MPXV.

The objective of the present study is to describe the clinical, biological, virological, pathophysiological and immunological aspects in the short and medium term of persons vaccinated against and infected with MPXV.

Read the detailed description

Descriptive, prospective, monocentric, longitudinal study. Subjects will be enrolled during their consultation at CMIP as part of their curative or preventive management of MPXV disease.

At the time of the appointment dedicated to vaccination or as part of the diagnosis of the infection, the clinician will explain the study in progress and will propose to the individual to participate if he/she is eligible.

If so, after signing the informed consent form, the individual will be included in the study.

The collection of socio-demographic, clinical and treatment data will be done on an eCRF at each study visit.

Biological samples (blood and/or urine samples and/or swabs for viruses) will also be taken at each study visit.

The samples will be used for the following biological analyses

  • serological analyses
  • sero-neutralization analysis by different techniques
  • cytometric analyses and biomarker measurements
  • virological analyses
  • genetic analysis.
02

Conditions studied

  • Monkey Pox

Keywords

  • vaccination
  • infection
  • monkey pox virus
  • outbreak
  • immunization
03

In context

Mpox, Monkeypox

72 studies on the registry are indexed under Mpox, Monkeypox; 29 are open to participants now.

This study's planned enrollment of 330 is close to the median of 305 across 36 interventional studies indexed under Mpox, Monkeypox.

Browse Mpox, Monkeypox studies →

Lead sponsor

Institut Pasteur is the lead sponsor of 99 studies on the registry; 41 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult,
  • eligible for MPXV vaccination according to HAS criteria or suspected of MPXV infection
  • whose health status is compatible with a 45 ml single blood sample
  • who have consented to participate in the study
  • who are covered by a Social Health Insurance plan

Exclusion criteria

Exclusion Criteria:

  • Person with MPXV vaccination without proof of vaccination.
  • For persons presenting for MPXV vaccination: presence of a to vaccination other than a current infection.
  • Pregnant and lactating women
  • Person unable to give to participate
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
330 participants (estimated)

Study arms

  • Other
    Individuals coming to CMIP for MONKEYPOX disease management

    * 300 individuals eligible for MPXV vaccination and * 30 individuals suspected of MPXV infection.

    Other: Blood sample collection · Other: urine sample collection

Interventions

  • OtherBlood sample collection

    Blood sample collection between inclusion and 12 months after inclusion

  • Otherurine sample collection

    urine sample collection at inclusion

06

What researchers measure

Primary outcomes

  1. Characterize the immune responses of the individual to MPXV vaccination

    Seroneutralizing capacity of serum 14 days (+/- 2 days) after the last dose administered

    Time frame: 5 years

  2. Characterize the developed cellular immunity and circulating levels of immune signaling molecules in individuals after MPXV vaccination and MPXV infection

    Measurement of activation of dendritic cells, NK cells, B cells and various T cells and levels of involved cytokines in individuals after MPXV vaccination and MPXV infection

    Time frame: 5 years

  3. Map the presence of MPXV in infectious sites of infected patients by qualitative and quantitative analyses comparing primary lesions, secondary lesions and healthy skin

    Measurement of the number of clinical sites in which MPXV is demonstrated, the level of associated viral load, the cellular distribution of lesional viral load on biopsies of ulcerated areas

    Time frame: 5 years

  4. Characterize gene expression profiling in the peripheral blood of the individual after MPXV vaccination and the individual after MPXV infection

    Transcriptomic analysis of gene expression of immunological markers in individuals after MPXV vaccination and MPXV

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2022 (actual). Primary completion is estimated for Dec 2026, 48 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2022
First posted
Nov 28, 2022
StartActual
Dec 1, 2022
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Dec 19, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05627713
Lead sponsor
Institut Pasteur
Collaborators
Centre Médical de l'Institut Pasteur
Responsible party
Sponsor
First posted
Nov 28, 2022
Start date
Dec 1, 2022
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Dec 19, 2023

Study contacts

Fabien Taieb, MD
Contact
fabien.taieb@pasteur.fr
+ 33(0)1 40 61 38 44
Paul-Henri Consigny, MD
Contact
paul-henri.consigny@pasteur.fr
+33(0)1 45 68 81 15
Fabien Taieb, MD
principal investigator · Institut Pasteur

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion